Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

The impact of bariatric surgery on nonalcoholic steatohepatitis

Semin Liver Dis. 2012 Feb;32(1):80-91. doi: 10.1055/s-0032-1306428. Epub 2012 Mar 13.

Abstract

Nonalcoholic steatohepatitis (NASH) is a stage of nonalcoholic fatty liver disease (NAFLD), and in most patients, is associated with obesity and the metabolic syndrome. The current best treatment of NAFLD and NASH is weight reduction with the current options being life style modifications, with or without pharmaceuticals, and bariatric surgery. Bariatric surgery is an effective treatment option for individuals who are severely obese (body mass index ≥ 35 kg/m(2)), and provides for long-term weight loss and resolution of obesity-associated diseases in most patients. Regression and/or histologic improvement of NASH have been documented after bariatric surgery. We review the available literature reporting on the impact of the various bariatric surgery techniques on NASH.

Publication types

  • Review

MeSH terms

  • Bariatric Surgery / adverse effects
  • Bariatric Surgery / methods*
  • Fatty Liver / pathology
  • Fatty Liver / surgery*
  • Ghrelin / metabolism
  • Glucagon-Like Peptide 1 / metabolism
  • Humans
  • Non-alcoholic Fatty Liver Disease
  • Obesity / surgery
  • Peptide YY / metabolism
  • Weight Loss / physiology*

Substances

  • Ghrelin
  • Peptide YY
  • Glucagon-Like Peptide 1